Targovax strengthens 2-year survival rate in resected pancreatic cancer with TG01
Median overall survival was 33.4 months compared to 27.6 months in the ESPAC4 trial An optimized dosing regimen has now been defined for the planned randomized trialOslo, Norway, 24 May 2018 - Targovax ASA (“Targovax” or “the Company”; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, today announces the completion of the 32-patient phase I/II clinical trial evaluating TG01 in resected pancreatic cancer in combination with standard of care chemotherapy (gemcitabine). Median overall survival (mOS) for all 32 patients was 33.4